 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SC-006 / AbbVie
Journal: Beyond cold chain: Exploring bacterial-viral interactions and disinfection strategies for norovirus persistence on organic lettuce under temperature fluctuations. (Pubmed Central) - Aug 26, 2025
Transmission electron microscopy (TEM) and molecular docking analysis showed MNV-1 particles binding to HBGA-like substances in SEPS-SC006, potentially enhancing viral resistance. Overall, temperature fluctuations and bacterial-viral interactions affected MNV-1 survival, and the combination of UV and ClO2 offers a promising approach for ensuring fresh produce safety throughout the food cold chain.
- | SC-006 / AbbVie, SC-002 / AbbVie, tamrintamab pamozirine (SC-003) / AbbVie
Journal: Molecular Characterization of Clostridium botulinum Isolates from Sichuan Province, China (1990-2024). (Pubmed Central) - Aug 6, 2025
In addition, analysis of BoNTs subtypes demonstrated that the types of BoNTs causing botulism in Sichuan were mainly types A, B, and E. Among them, some rare subtypes of BoNT reported for the first time in China, such as BoNT/B4, BoNT/E12, and BoNT/A5(B3), and no specific subtypes were predominant in the botulism incidents. This study is critical for disease surveillance and early warning systems, while also providing a basis for food safety regulation, clinical diagnosis, and treatment in the future.
- ||||| SC-006 / AbbVie
Clinical: Awesome recruitment site visits to a couple of fantastic #ICUs @VCUHealth and @sentarahealth/@EVMSedu. #FutureIsBright #CellDirectedTherapy #SCD006 #ClinicalTrials @SeaStarMedical @Nasdaq $ICU (Twitter) - Nov 16, 2022
- || SC-006 / AbbVie
"Vision without execution is hallucination." - Thomas Edison #CellDirectedTherapy #SCDHDEinPeds #SCD006 $ICU @SeaStarMedical (Twitter) - Nov 15, 2022
- || SC-006 / AbbVie
Time to get to work! #SCDisCellDirectedTherapy #CDET (Cell Directed Extracorporeal Therapy) #SCDHDEforPeds #SCD006 $ICU (Twitter) - Oct 29, 2022
- |||| SC-006 / AbbVie
Awesome visit with Drs. Junior Uduman and Mohamed Zidan. What an awesome #nephrology #critcare #research presence! Easy to forecast that @HenryFordHealth will be one of our lead sites for #SCD006 #MedTwitter (Twitter) - Sep 20, 2022
- | SC-006 / AbbVie
Journal: Proteiniclasticum aestuarii sp. nov., isolated from tidal flat sediment, and emended descriptions of the genus Proteiniclasticum and Proteiniclasticum ruminis. (Pubmed Central) - Apr 15, 2022
nov. is proposed, with the type strain SCR006 (=KCTC 25245= JCM 34531).
- SC-006 / AbbVie
SC006 - Complexities and Complications: Case-based Conversations in Mechanical Thrombectomy (Stroke Central, Learning Studio 2, Hall C, Booth 647) - Feb 22, 2022 - Abstract #ISC2022ISC_1579;
These cases will highlight real-world issues we face with some thrombectomy patients in the angio suite. Each case will be 15 minutes total with various issues presented and then a 5 minute networking session.
- budigalimab (ABBV-181) / AbbVie
First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1810;
P1
Each case will be 15 minutes total with various issues presented and then a 5 minute networking session. SC-006 dose escalation was limited by thrombocytopenia observed below the predicted efficacious dose, leading to study termination.
- ||| SC-006 / AbbVie, budigalimab (ABBV-181) / AbbVie
Trial termination, Combination therapy, Metastases: A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 29, 2019
P1, N=29, Terminated, Sponsor: AbbVie
SC-006 dose escalation was limited by thrombocytopenia observed below the predicted efficacious dose, leading to study termination. Completed --> Terminated; Strategic considerations
- || SC-006 / AbbVie, budigalimab (ABBV-181) / AbbVie
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 9, 2019
P1, N=29, Completed, Sponsor: AbbVie
Completed --> Terminated; Strategic considerations Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Mar 2019 | Trial primary completion date: Jul 2020 --> Mar 2019
- || SC-006 / AbbVie, budigalimab (ABBV-181) / AbbVie
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 29, 2019
P1, N=29, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Mar 2019 | Trial primary completion date: Jul 2020 --> Mar 2019 Recruiting --> Active, not recruiting | N=108 --> 29
- ||| SC-006 / AbbVie, budigalimab (ABBV-181) / AbbVie
Enrollment open, Combination therapy, Metastases: A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - Mar 31, 2017
P1, N=108, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting | N=108 --> 29 Not yet recruiting --> Recruiting
- ||| SC-006 / AbbVie, budigalimab (ABBV-181) / AbbVie
New P1 trial, Combination therapy, Metastases: A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 30, 2017
P1, N=108, Not yet recruiting, Sponsor: AbbVie